Fig. 2: Assessment of hexamerisation enhancement and antigen binding of IgG1 μtp constructs. | Communications Biology

Fig. 2: Assessment of hexamerisation enhancement and antigen binding of IgG1 μtp constructs.

From: On-target IgG hexamerisation driven by a C-terminal IgM tail-piece fusion variant confers augmented complement activation

Fig. 2

a Rituximab mAb constructs were concentrated up to 70 mg/ml and diluted to the required concentrations and analysed by SE-HPLC for the percentage of monomeric and multimeric species. Shown are SE-HPLC chromatagrams of hIgG1 wild-type and hIgG1 μtp C575S overlaid with purified hIgG1 μtp pre-formed hexamer trace prior to concentration, antibody concentrated to 20 mg/ml and 70 mg/ml, and post dilution back to 1 mg/ml. b Ramos cells were opsonised with rituximab hIgG1 μtp mAb at 10 μg/ml and binding measured by secondary anti-human Fc-APC-labelled antibody. Solid grey histograms indicate matched Herceptin hIgG wild-type and hIgG μtp isotype control mAb. c Antibody binding (MFI) over a concentration range of rituximab hIgG μtp and isotype control hIgG μtp mAb binding Ramos cells (representative data shown).

Back to article page